Royal Bank Of Canada Reaffirms Outperform Rating for Valeant Pharmaceuticals Intl Inc (VRX)
Royal Bank Of Canada restated their outperform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) in a research report report published on Monday morning, StockTargetPrices.com reports. The firm currently has a C$46.00 price objective on the specialty pharmaceutical company’s stock.
Other equities research analysts have also recently issued reports about the company. TD Securities reissued a hold rating and set a C$38.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Thursday, July 14th. Scotiabank decreased their price target on Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a sector perform rating on the stock in a report on Monday, July 25th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of C$38.67.
Valeant Pharmaceuticals Intl (TSE:VRX) opened at 31.29 on Monday. The firm has a 50-day moving average price of $36.42 and a 200-day moving average price of $35.30. The company’s market capitalization is $10.87 billion. Valeant Pharmaceuticals Intl has a 52 week low of $24.32 and a 52 week high of $240.40.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.